BACKGROUND: The goal of antiretroviral therapy (ART) is to reduce HIV-related morbidity and mortality by suppressing HIV replication. The prognostic value of persistent low-level viremia (LLV), particularly for clinical outcomes, is unknown. OBJECTIVE: Assess the association of different levels of LLV with virological failure, AIDS event, and death among HIV-infected patients receiving combination ART. METHODS: We analyzed data from 18 cohorts in Europe and North America, contributing to the ART Cohort Collaboration. Eligible patients achieved viral load below 50 copies/ml within 3-9 months after ART initiation. LLV50-199 was defined as two consecutive viral loads between 50 and 199 copies/ml and LLV200-499 as two consecutive viral loads between 50 and 499 copies/ml, with at least one between 200 and 499 copies/ml. We used Cox models to estimate the association of LLV with virological failure (two consecutive viral loads at least 500 copies/ml or one viral load at least 500 copies/ml, followed by a modification of ART) and AIDS event/death. RESULTS: Among 17 902 patients, 624 (3.5%) experienced LLV50-199 and 482 (2.7%) LLV200-499. Median follow-up was 2.3 and 3.1 years for virological and clinical outcomes, respectively. There were 1903 virological failure, 532 AIDS events and 480 deaths. LLV200-499 was strongly associated with virological failure [adjusted hazard ratio (aHR) 3.97, 95% confidence interval (CI) 3.05-5.17]. LLV50-199 was weakly associated with virological failure (aHR 1.38, 95% CI 0.96-2.00). LLV50-199 and LLV200-499 were not associated with AIDS event/death (aHR 1.13, 95% CI 0.81-1.68; and aHR 0.95, 95% CI 0.62-1.48, [corrected] respectively). CONCLUSION: LLV200-499 was strongly associated with virological failure, but not with AIDS event/death. Our results support the US guidelines, which define virological failure as a confirmed viral load above 200 copies/ml.
BACKGROUND: The goal of antiretroviral therapy (ART) is to reduce HIV-related morbidity and mortality by suppressing HIV replication. The prognostic value of persistent low-level viremia (LLV), particularly for clinical outcomes, is unknown. OBJECTIVE: Assess the association of different levels of LLV with virological failure, AIDS event, and death among HIV-infected patients receiving combination ART. METHODS: We analyzed data from 18 cohorts in Europe and North America, contributing to the ART Cohort Collaboration. Eligible patients achieved viral load below 50 copies/ml within 3-9 months after ART initiation. LLV50-199 was defined as two consecutive viral loads between 50 and 199 copies/ml and LLV200-499 as two consecutive viral loads between 50 and 499 copies/ml, with at least one between 200 and 499 copies/ml. We used Cox models to estimate the association of LLV with virological failure (two consecutive viral loads at least 500 copies/ml or one viral load at least 500 copies/ml, followed by a modification of ART) and AIDS event/death. RESULTS: Among 17 902 patients, 624 (3.5%) experienced LLV50-199 and 482 (2.7%) LLV200-499. Median follow-up was 2.3 and 3.1 years for virological and clinical outcomes, respectively. There were 1903 virological failure, 532 AIDS events and 480 deaths. LLV200-499 was strongly associated with virological failure [adjusted hazard ratio (aHR) 3.97, 95% confidence interval (CI) 3.05-5.17]. LLV50-199 was weakly associated with virological failure (aHR 1.38, 95% CI 0.96-2.00). LLV50-199 and LLV200-499 were not associated with AIDS event/death (aHR 1.13, 95% CI 0.81-1.68; and aHR 0.95, 95% CI 0.62-1.48, [corrected] respectively). CONCLUSION: LLV200-499 was strongly associated with virological failure, but not with AIDS event/death. Our results support the US guidelines, which define virological failure as a confirmed viral load above 200 copies/ml.
Authors: Rimke Bijker; Sasisopin Kiertiburanakul; Nagalingeswaran Kumarasamy; Sanjay Pujari; Ly P Sun; Oon T Ng; Man P Lee; Jun Y Choi; Kinh V Nguyen; Yu J Chan; Tuti P Merati; Do D Cuong; Jeremy Ross; Awachana Jiamsakul Journal: Antivir Ther Date: 2020
Authors: Jennifer S Lee; Stephen R Cole; David B Richardson; Dirk P Dittmer; William C Miller; Richard D Moore; Mari Kitahata; Christopher Mathews; Kenneth Mayer; Elvin Geng; Chad J Achenbach; Joseph J Eron Journal: AIDS Date: 2017-09-10 Impact factor: 4.177
Authors: Jean-Médard Kankou; Olivier Bouchaud; Nathalie Lele; Marguerite Guiguet; Bruno Spire; Maria Patrizia Carrieri; Sophie Abgrall Journal: J Immigr Minor Health Date: 2019-12
Authors: Julia Fleming; W Christopher Mathews; Richard M Rutstein; Judith Aberg; Charurut Somboonwit; Laura W Cheever; Stephen A Berry; Kelly A Gebo; Richard D Moore Journal: AIDS Date: 2019-11-01 Impact factor: 4.177
Authors: Jennifer A Fulcher; Marjan Javanbakht; Chelsea L Shover; Amy Ragsdale; Ron Brookmeyer; Steven Shoptaw; Pamina M Gorbach Journal: Drug Alcohol Depend Date: 2021-02-16 Impact factor: 4.492
Authors: K Rivet Amico; Jessica Crawford; Ini Ubong; Jane C Lindsey; Aditya H Gaur; Keith Horvath; Rachel Goolsby; Megan Mueller Johnson; Ronald Dallas; Barbara Heckman; Teresa Filipowicz; Melissa Polier; Betty M Rupp; Michael Hudgens Journal: AIDS Patient Care STDS Date: 2021-05 Impact factor: 5.078